GlaxoSmithKline plc has reported that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp, currently members of the GSK Board, will not stand for re-election to the Board at the Annual General Meeting (AGM) taking place in 2013. Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009. Judy Lewent will succeed Tom de Swaan as Chair of the Audit and Risk Committee with effect from January 2013. Ms Lewent has been a member of the Audit and Risk Committee since April 2011. In addition, Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director at the close of GSKs AGM in 2013. James Murdoch has also decided not to stand for re-election to the Board at GSKs AGM in 2012. Sir Christopher Gent is Chairman of GSK.

Healthcare company Abbott Laboratories Limited, has recorded a 4.1% rise in sales to $10.4 billion. New markets represented approximately 25% of total sales at $2.5 billion. The global company has a UK base in Maidenhaed, Berkshire. In 2011, Abbott continued to expand its business and launched several new products or indications across their Pharmaceuticals, Medical Products, Nutritionals and Diagnostics businesses. Miles D. White is Chairman and Chief Executive Officer of Abbot Laboratories Limited.

PZ Cussons, a consumer products group in Europe, Asia and Africa, announces recorded interim results for the six months ended 30 November 2011.  Revenue up 10.5% to £414.0m, operating profit down 12.8% to £40.1m. Richard Harvey is Chairman.

Alliance Boots, the Chemist chain, has recorded like-for-like sales growth of 4.1% in the five weeks to the end of December 2011. Group revenue increased by 14.1% compared to 2010. Stefano Pessina is Executive Chairman.